Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo
Authors:
- Xiaoli WeiXWXiaoli Wei
- Jun QianJQJun Qian
- Linglin FengLFLinglin Feng
- Jianhua ZhuJZJianhua Zhu
- Weiyue LuWLWeiyue Lu
- 1 June 2012
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 160 (3) , 630-636
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1British Journal of Cancer, 2011
- Paclitaxel Tumor-Priming Enhances siRNA Delivery and Transfection in 3-Dimensional Tumor CulturesMolecular Pharmaceutics, 2011
- Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastomaJournal of Clinical Investigation, 2011
- Inhibition of brain tumor growth by intravenous poly(β- l -malic acid) nanobioconjugate with pH-dependent drug releaseProceedings of the National Academy of Sciences, 2010
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Transvascular delivery of small interfering RNA to the central nervous systemNature, 2007
- Targeted delivery of proteins across the blood–brain barrierProceedings of the National Academy of Sciences, 2007
- Cationic Albumin–Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumors via Intravenous AdministrationCancer Research, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesisNuclear Medicine and Biology, 2004